• Explore /
  • Poster
  • / A phase II trial of regorafenib as a single agent in patients with advanced and metastatic biliary tract carcinoma and first-line chemotherapy failure.

A phase II trial of regorafenib as a single agent in patients with advanced and metastatic biliary tract carcinoma and first-line chemotherapy failure.

Abstract Poster

Authors

null

Anuj Kishor Patel

University of Pittsburgh, Pittsburgh, PA

Anuj Kishor Patel , Ronald G. Stoller , John C. Rhee , Barry C. Lembersky , James Ohr , James J. Lee , Nathan Bahary , Edward Chu , Weijing Sun

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02053376

Citation

J Clin Oncol 33, 2015 (suppl 3; abstr TPS498)

DOI

10.1200/jco.2015.33.3_suppl.tps498

Abstract #

TPS498

Poster Bd #

F13

Abstract Disclosures

Similar Posters

First Author: Richard D. Kim

First Author: Yongkun Sun

First Author: Nick Pavlakis

First Author: John Ebben